Replies to post #141557 on Medical Marijuana Inc (MJNA)

[MuRk MoNsT3R]

What percent of Dixie does mjna own 60% or 40% and what do you make of trips comments that ultimately he wants to get bought out by a big player ? Thnx

[@LaughinPaulRyan]

... MMOD - HempMedsPX ...

Executive Office of the President; Office of National Drug Control Policy (ONDCP) (F.R. Page 53789) holds a conference on 9/16/13 sponsored by the Substance Abuse and Mental Health Administration (SAMHSA), the Office of the National Coordinator for Health Information Technology, and the National Institutes of Health's Office of Behavioral and Social Sciences Research, on "Technology Innovations for Substance Abuse and Mental Health Treatment," highlighting promising innovations for treating substance abuse and mental health disorders and advances in health information technologies (HIT). - source

The goal of this conference is to highlight advances in health information technologies (HIT) for behavioral health, and promote technology advances and dissemination of evidence-based tools that address patient safety and the advancement of successful prevention, treatment and recovery. The specific conference objectives are to: (1) Promote evidence-based tools to advance treatment of substance use and mental health disorders; (2) advance the Administration's 2010National Drug Control Strategy blueprint and the HIT initiatives at SAMHSA and the Office of the National Coordinator; and (3) encourage the use of technologies to improve health, improve quality of care, and increase patient engagement.

Watch Live Video Feed Here

KannaLife Sciences, Inc. (“KannaLife”) announces its collaboration with two experienced drug discovery organizations: Advanced Neural Dynamics and IteraMed. KannaLife will fund a new drug discovery project related to a laboratory validated phytochemical. The founding science is based on the licensed technology of Dr. A. J. Hampson at the Laboratory of Cellular and Molecular Regulation within the National Institutes of Mental Health. Dr. Hampson’s research has shown that this phytochemical is neuroprotective in cortical neuronal cultures exposed to toxic levels of glutamate or oxidative stress.IteraMed and Advanced Neural Dynamics are located at the Pennsylvania Biotechnology Center. The Pennsylvania Biotechnology Center is a 112,000 square-foot biotechnology incubator in Doylestown, PA, houses one of the richest botanical collections in the world and is home to several and approximately thirty life sciences companies and several non-profit organizations. Dean Petkanas, CEO of KannaLife, stated: “This opportunity to begin our research and development program at the Pennsylvania Biotechnology Center, would not be possible without the support and financial backing of our investors, Medical Marijuana, Inc. and CannaVEST. The Pennsylvania Biotechnology Center has a scientifically rich environment in liver, neurological and botanical science, areas vital to KannaLife. Having this shared vision and support from MJNA and CannaVest is crucial to the long range research and development efforts planned between KannaLife, IteraMed and Advanced Neural Dynamics.”About Advanced Neural Dyanamics (“AND”): AND is a drug discovery company founded in October 2008 by Dr. Douglas Brenneman, an expert in the pharmacology of small molecules and neuropeptides. AND’s focuses on developing novel small molecule neuroprotective therapeutics for the treatment of neurological diseases. AND’s neuroprotective drug discovery strategy is differentiated by the use of primary neural cultures derived from the central nervous system combined with biochemical, molecular and immunocytochemical methods that measure cellular responses to identify products that will be safer and more effective than currently approved therapies. - source



Maia Szalavitz reported in her article on Time.com that “[r]esearchers led by Markus Leweke of the University of Cologne in Germany studied 39 people with schizophrenia who were hospitalized for a psychotic episode. Nineteen patients were treated with amisulpride, an antipsychotic medication that is not approved in the U.S., but is comparable to other medications that are.The rest of the patients were given cannabidiol (CBD), a substance found in marijuana that is thought to be responsible for some of its mellowing or anxiety-reducing effects. Unlike the main ingredient in marijuana, THC, which can produce psychotic reactions and may worsen schizophrenia, CBD has antipsychotic effects, according to previous research in both animals and humans.”“The results were amazing,” says Daniele Piomelli, professor of pharmacology at the University of California-Irvine and a co-author of the study. “Not only was [CBD] as effective as standard antipsychotics, but it was also essentially free of the typical side effects seen with antipsychotic drugs.” -source